Abstract
Introduction: BAY 94-9027, a site-specifically PEGylated, B-domain‒deleted recombinant factor VIII (FVIII) with extended half-life, demonstrated efficacy for bleed prevention and treatment in previously treated adolescents and adults with severe haemophilia A. Aim: To assess BAY 94-9027 in children with severe haemophilia A. Methods: In the two-part PROTECT VIII Kids study,
... read more